These metabolic changes could affect cancer cell growth and proliferation by increasing the provision of glucose to cancer cells, and at the same time by stimulating the insulin receptor (IR)/PI3K/AKT/mTORC1 pathway and promoting tumor cell resistance to everolimus. This evidence concerns the gene INSR and neoplasm.